IL1A and cancer: Additionally, encapsulation of IL‐1α into CPH:SA MPs did not reduce the bioactivity of IL‐1α nor the in vivo anti‐tumor immune response which are all promising indicators for further study as an acceptable cancer immunotherapeutic strategy.